Dr. Jaime L. Schneider, M.D., Ph.D., is a medical oncologist at the Massachusetts General Hospital specializing the care of patients with thoracic malignancies. Dr. Schneider received her B.A. from Northwestern University and her M.D./Ph.D. degrees from the Albert Einstein College of Medicine. After completing her residency in internal medicine at MGH and fellowship in medical oncology in the Dana-Farber/Harvard Cancer Care program, she joined the faculty at the MGH Cancer Center and Harvard Medical School. Dr. Schneider has an active practice caring for patients in the MGH Thoracic Oncology Program. As a basic/translational investigator, Dr. Schneider’s research focuses on non-small cell lung cancer, with a specific interest in cancers that harbor oncogenic driver alterations. Using primary tumor samples and patient-derived models, she is using integrative metabolomics approaches to investigate whether specific onco-genotypes in lung cancer confer metabolic vulnerabilities and how metabolic reprogramming drives resistance to targeted therapies.

Dr. Schneider has received research funding from A Breath of Hope Lung Foundation, Lung Cancer Research Foundation/ALK-Positive, American Cancer Society, Gilead, Harvard Medical School Shore Award Program, ROS1ders Innovation Award, and she has a K12 Career Development Award. She is the proud recipient of honors including the ASCI Early Generation Physician Scientist Award, IASLC TTLC Education Award, Mass General Brigham Teaching Award, Forbeck Research Foundation Scholar, AACR Scholar in Training Award, and 40 Under 40 in Cancer. Dr. Schneider is on the editorial board of Translational Cancer Research and is a member of the International Association for the Study of Lung Cancer, American Association for Cancer Research, and American Society of Clinical Oncology. As a physician-scientist, Dr. Schneider is passionate about treating patients with lung cancer and is committed to developing novel therapeutic approaches using innovative scientific tools.